Thomas Yau
Impact in
- Hepatology top 0.1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
Papers in
- Oncology 102
- Cancer Immunotherapy and Biomarkers 48
- Colorectal Cancer Treatments and Studies 27
- Pancreatic and Hepatic Oncology Research 21
- Hepatology 98
- Hepatocellular Carcinoma Treatment and Prognosis 93
- Co-authors
- Ann‐Lii Cheng (30 shared papers)Richard S. Finn (24 shared papers)Ronnie T. P. Poon (15 shared papers)Masatoshi Kudo (34 shared papers)Pierre Chan (18 shared papers)Philippe Merle (14 shared papers)Andrew X. Zhu (16 shared papers)Tzy‐Jyun Yao (4 shared papers)
- Journals
- Journal of Clinical Oncology (34 papers)Annals of Oncology (32 papers)The Oncologist (7 papers)Cancer Research (6 papers)Liver Cancer (6 papers)
- Partner nations
- Hong KongChinaUnited States
In The Last Decade
Thomas Yau
203 papers receiving 9.4k citations
Thomas Yau's Hit Papers
Peers
Comparison fields: 5 of 114
- Hepatology 4.1k
- Oncology 3.6k
- Cancer Research 1.3k
- Pathology and Forensic Medicine 1.1k
- Immunology 1.0k
Countries citing papers authored by Thomas Yau
This map shows the geographic impact of Thomas Yau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Yau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Yau more than expected).
Fields of papers citing papers by Thomas Yau
This network shows the impact of papers produced by Thomas Yau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Yau. The network helps show where Thomas Yau may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas Yau, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 211 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial Hit paper breakdown → | 2019 | 1329 |
| 2 | Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2015 | 567 |
| 3 | Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular Carcinoma Hit paper breakdown → | 2014 | 505 |
| 4 | CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) Hit paper breakdown → | 2019 | 499 |
| 5 | A Subpopulation of CD26+ Cancer Stem Cells with Metastatic Capacity in Human Colorectal Cancer Hit paper breakdown → | 2010 | 440 |
| 6 | Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma Hit paper breakdown → | 2022 | 366 |
| 7 | 2016 | 345 | |
| 8 | 2020 | 286 | |
| 9 | 2019 | 179 | |
| 10 | 2019 | 159 | |
| 11 | 2020 | 135 | |
| 12 | 2008 | 132 | |
| 13 | 2006 | 119 | |
| 14 | 2014 | 110 | |
| 15 | 2013 | 110 | |
| 16 | 2021 | 104 | |
| 17 | 2018 | 102 | |
| 18 | 2020 | 94 | |
| 19 | 2011 | 88 | |
| 20 | 2012 | 87 |
About Thomas Yau
Thomas Yau is a scholar working on Oncology, Hepatology, Pulmonary and Respiratory Medicine, Cancer Research and Epidemiology, having authored 211 papers that have together received 9.5k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (93 papers), Cancer Immunotherapy and Biomarkers (48 papers), Colorectal Cancer Treatments and Studies (27 papers), Pancreatic and Hepatic Oncology Research (21 papers), Ferroptosis and cancer prognosis (13 papers), Hepatitis B Virus Studies (11 papers), Cancer Mechanisms and Therapy (11 papers) and Cancer Genomics and Diagnostics (11 papers). The work is most often cited by research in Hepatology (4.1k citations), Oncology (3.6k citations), Cancer Research (1.3k citations), Pathology and Forensic Medicine (1.1k citations) and Immunology (1.0k citations). Thomas Yau has collaborated with scholars based in Hong Kong, China and United States. Frequent co-authors include Ann‐Lii Cheng, Richard S. Finn, Ronnie T. P. Poon, Masatoshi Kudo, Pierre Chan, Philippe Merle, Andrew X. Zhu, Tzy‐Jyun Yao, Vikki Tang and Baek‐Yeol Ryoo. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The Oncologist, Cancer Research and Liver Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.